TrxR-IN-7 

TrxR-IN-7 is a thioredoxin reductase (TrxR) inhibitor with an IC₅₀ of 3.5 μM. TrxR-IN-7 induces reactive oxygen species (ROS) generation and apoptosis in tumor cells. TrxR-IN-7 can be used for the research of liver cancer and breast cancer^[1].

TrxR-IN-7 (Compound 14f) potently inhibits isolated TrxR activity with an IC₅₀ of 3.5 μM^[1].
TrxR-IN-7 (72 h) inhibits the proliferation of HepG2 cells with an IC₅₀ of 19.45 μM and MCF-7 cells with an IC₅₀ of 28.22 μM^[1].
TrxR-IN-7 (12.5-50 μM; 24 h) inhibits intracellular TrxR activity in HepG2 cells in vitro in a concentration-dependent manner following 24 hours of treatment^[1].
TrxR-IN-7 (6.25-12.5 μM; 3-12 h) induces ROS generation in HepG2 cells in both concentration- and time-dependent manners, increasing levels of hydrogen peroxide and superoxide anions^[1].
TrxR-IN-7 (12.5-50 μM; 24 h) induces both early and late apoptosis in HepG2 cells in a concentration-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

347.41

C₂₂H₂₁NO₃

N#CC1=CC=C([C@@]2(O)CCC[C@@]3(C)CC(C(C=C4)=O)=C(C[C@]32[H])C4=O)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Huang B, et al. Synthesis and discovery of simplified pleurotin analogs bearing tricyclic core as novel thioredoxin reductase inhibitors. Eur J Med Chem. 2025;285:117242.  [Content Brief]